Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

PANDORA Doctoral network on discovering pathomechanisms and novel drug optimization for AMD

Coordinator
Eberhard Karls Universitaet Tuebingen, Germany
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€4.0m
Total cost
—
Partners
16 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101312030

What the project is doing

In the project's own words, from its summary on CORDIS.

PANDORA will create a multidisciplinary, intersectoral European Doctoral Network focusing on complement system-mediated pathomechanisms and therapy development for Age-related macular degeneration (AMD). AMD, major cause of blindness in the elderly population, affects daily activities of ca. 200 million people worldwide, placing a major burden on national health systems and impairing patients’ quality of life. The complement system, known for its role in innate immune surveillance, is a major pathogenic driver in AMD, also involved in various other diseases, including sepsis, neurodegenerative, kidney, vascular diseases and cancer.

We and others have recently demonstrated the importance of locally produced complement factors and non-canonical complement functions in the retina, affecting energy metabolism, protein degradation, mitochondrial stability, autophagy and lysophagy, which are found to be impaired in AMD. PANDORA will exploit state-of-the art model systems and techniques, including ex vivo multicellular, stem-cell derived and murine models, omics, imaging, biochemistry, histology, functional assays and computational modelling, to study in depth the different complement functions relevant to AMD and to find potential biomarkers for stratification and disease monitoring.

PANDORA further aims to develop innovative therapeutic approaches, using gene therapy, compound screening, optimizing drug delivery to the retina, and a novel ultra-high resolution multimodality imaging system to monitor disease progression and treatment efficacy in vivo and in patients. PANDORA will train Doctoral Candidates as the next generation of European translational scientists in vision and medical research, and provides every student with the tools for a successful scientific career in academia or industry.

Our multidisciplinary network offers a unique opportunity to expand the understanding and therapeutics for AMD in Europe, and to bring research findings to benefit for patients.

Topics

Who is involved

OrganisationCityCountryRole
Eberhard Karls Universitaet TuebingenTuebingenGermanyCoordinator
Universite De FribourgFribourgSwitzerlandParticipant
Boehringer Ingelheim Pharma GmbH &co KgIngelheimGermanyAssociatedpartner
Idryma Technologias Kai ErevnasIrakleioGreeceParticipant
Kymatoniki Idiotiki Kefalaiouchiki EtaireiaHeraklionGreeceParticipant
Panepistimio KritisRethimnoGreeceAssociatedpartner
Fundacion Centro De Excelencia En Investigacion De Medicamentos Innovadores En AndaluciaArmilla GranadaSpainParticipant
Universidad De GranadaGranadaSpainAssociatedpartner
Ita-Suomen YliopistoKuopioFinlandParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Microfluidics Innovation CenterParisFranceParticipant
Sorbonne UniversiteParisFranceParticipant
Universite De ToulouseToulouseFranceAssociatedpartner
Retina International CLGDublin 2IrelandAssociatedpartner
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI